Wednesday, 18 Oct 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
24 May 2017 News Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis
23 May 2017 Social Kevzara-the 2nd IL-6 inhibitor approved for use in RA; priced at $39K, 30% below competition https://t.co/mzIOOhEnMe https://t.co/2U3J2sskum
23 May 2017 Social FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis. See RheumNow report. https://t.co/73UieZpbn1 https://t.co/HjUzi0H6OL
23 May 2017 News Actemra - First FDA Approved Drug for Giant Cell Arteritis
22 May 2017 Social @naseema22537544 @DrSimply The new updated PI says its to be given with a tapering course of steroids. https://t.co/SCaiX1FDQx
18 May 2017 Social RT @DrPetryna: @RheumNow could ustekinumab potentially be used in treatment of refractory GCA? Evidence suggests it might https://t.co/Ydr0…
15 May 2017 Social In #Crohns disease Tofacitinib fails to maintain remission in randomized W/D, results of 2 Placebo RCT. https://t.co/9KXQxdq9kw
12 May 2017 Social Uptacitinib (Abbvie Jak 1 inhibitor) shows efficacy in Crohns dz (CELESTE RCTl) w/ remission rates at 6 &24 mg bid https://t.co/ssZT2D6nWk
10 May 2017 Social Responses to Orencia may be dependent on baseline memory B cells (CD38+ CD27+) https://t.co/zro040Y54W
07 May 2017 Social FDA has accepted Sanofi/Regenerons resubmitted BLA for Sarilumab (IL-6 inhib) for RA w/ PFUFA action date 5/22/17 https://t.co/F9txx9QwLz
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response https://t.co/rLn6aJowry
04 May 2017 News Tofacitinib Effective in Ulcerative Colitis
04 May 2017 Social Pfizer submitted tofacitinib NDA to FDA for psoriatic arthritis. FDA prev denied the NDA for psoriasis w/ CR letter. https://t.co/bDmnc8QF3c
04 May 2017 Social Fostamatinib (Tavalisse) Syk inhib failed in RA, has been studied in ITP, new NDA for ITP submitted to FDA by Rigel. https://t.co/Nwull2hiB3
01 May 2017 Social OPT 1&2 RCT show Tofacitinib to improve nail psoriasis: NAPSI75 scores PBO 6.8%, Tofa 5mg 16.9%, 10 mg 28.1% bid https://t.co/YCtVbkF5Cf
29 Apr 2017 Social RT @NYTHealth: You asked: What is it about so many medications that causes dryness in the mouth? Here's a short explanation. https://t.co/B…
26 Apr 2017 Social Sandoz biosimilars of Enbrel and Rituxan were recommened by CHMP for approval/use in the EU. EMA decision awaited https://t.co/zLrPlnKsZF
21 Apr 2017 Social Small study of 13 alopecia pts (2 totalis, 7universalis); Xeljanz Rx 7/13 had >50% regrowth w/in 9 mos, 2 d/c https://t.co/w5OxVvdIvQ
18 Apr 2017 Social How will new BIOSIMILAR biologic drugs affect PATIENTS - Make Your views count in a survey; Patients vote HERE>> https://t.co/Q0mXqI5rnc
17 Apr 2017 News Anti-IL-23 Therapy Effective in Crohn's Disease